Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

Only one is FDA-approved for hair loss. Topical minoxidil is FDA-approved specifically for the treatment of pattern baldness.

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

Jupiter Endovascular today announced the first two patients treated in a study of its Vertex pulmonary embolectomy system.

Some people of West African of descent face a higher risk of renal failure. New drugs based on gene research may help right ...

Nick Li is global HEOR lead for hemoglobinopathies at Vertex Pharmaceuticals. Below he explains why this type of research is ...

Ginkgo Bioworks introduces a protein large language model and API, developed with Google Cloud, to streamline drug discovery ...